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Background: Obstructive sleep apnea (OSA) is a very prevalent disorder. Here, we aimed
to develop and validate a practical questionnaire with yes-or-no answers, and to compare its
performance with other well-validated instruments: No-Apnea, STOP-Bang, and NoSAS.
Methods: A cross-sectional study containing consecutively selected sleep-lab subjects
underwent full polysomnography. A 4-item model, named GOAL questionnaire (gender,
obesity, age, and loud snoring), was developed and subsequently validated, with item-scoring
of 0–4 points (≥2 points indicating high risk for OSA). Discrimination was assessed by area
under the curve (AUC), while predictive parameters were calculated using contingency
tables. OSA severity was classified based on conventionally accepted apnea/hypopnea
index thresholds: ≥5.0/h (OSA≥5), ≥15.0/h (OSA≥15), and ≥30.0/h (OSA≥30).
Results: Overall, 7377 adults were grouped into two large and independent cohorts: derivation
(n = 3771) and validation (n = 3606). In the derivation cohort, screening of OSA≥5, OSA≥15, and
OSA≥30 revealed that GOAL questionnaire achieved sensitivity ranging from 83.3% to 94.0%
and specificity ranging from 62.4% to 38.5%. In the validation cohort, screening of OSA≥5,
OSA≥15, and OSA≥30, corroborated validation steps with sensitivity ranging from 83.7% to
94.2% and specificity from 63.4% to 37.7%. In both cohorts, discriminatory ability of GOAL
questionnaire for screening of OSA≥5, OSA≥15, and OSA≥30 was similar to No-Apnea, STOP-
Bang or NoSAS.
Conclusion: All four instruments had similar performance, leading to a possible greater
practical implementation of the GOAL questionnaire, a simple instrument with only four
parameters easily obtained during clinical evaluation.
Keywords: obstructive sleep apnea, polysomnography, screening, questionnaire, diagnosis
Introduction
Obstructive sleep apnea (OSA) is characterized by frequent partial or complete
upper airway collapse during sleep, resulting in intermittent hypoxemia and sleep
fragmentation.1 There is growing evidence that OSA plays a key role in the
pathogenesis of cardiovascular and metabolic diseases, as well as a clear associa-
tion with increased overall mortality and medical costs.2,3 OSA is very prevalent
disease,4–6 being that most recent estimates have suggested that nearly a billion of
people may be affected, with about 425 million individuals, aged 30 to 69, suffering
from moderate to severe OSA, worldwide.7
Correspondence: David Gozal
Department of Child Health, University of
Missouri School of Medicine, Columbia,
MO, USA
Email drdavidgozal@gmail.com
Nature and Science of Sleep Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Nature and Science of Sleep 2020:12 57–67 57
http://doi.org/10.2147/NSS.S238255
DovePress © 2020 Duarte et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
 
N
at
ur
e 
an
d 
Sc
ie
nc
e 
of
 S
le
ep
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
13
6.
11
5.
1 
on
 0
7-
Fe
b-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
The gold standard for the diagnosis of OSA is an
attended in-lab overnight polysomnography (PSG) test.1
However, this costly method is not readily available to
a large number of patients with suspected OSA, especially
in regions with limited economic resources.1,8 Due to the
high frequency of OSA, there is a significant cost in
evaluating all subjects with suspected OSA, leading to
long waiting times for testing.9 In this context, portable
diagnostic methods have been extensively implemented as
an alternative for the diagnosis of OSA in those adults
exhibiting a high pretest probability and absence of sig-
nificant comorbidity.1
The various screening instruments that have merged over
the years have been generally predicated on the clinical, demo-
graphic and anthropometric parameters that constitute the
major risk factors for OSA.8 The STOP-Bang questionnaire
is an 8-item acronym that can be easily completed.10 It was
developed and later validated in surgical subjects having
a high prevalence of OSA≥5: 73% (derivation cohort) and
69% (validation cohort).10 Subsequently, it was widely vali-
dated in several different settings: sleep clinic patients, surgical
patients, and general population.11–16 Conversely, NoSAS
score was derived and validated in population-based cohorts
(HypnoLaus and EPISONO, respectively).17 Afterwards, this
score was also validated in different settings, reporting ade-
quate performance as screening model for OSA: in
a multiethnic Asian cohort, in a hospital-based sample, in
depressive subjects, and in a sleep clinic.18–22
The No-Apnea23 tool is a newly developed and validated
screening instrument that includes only two objective para-
meters: neck circumference (NC) and age, with a total score
ranging from 0 to 9 (cutoff point ≥3 classifies patients at high
risk for OSA). In derivation and validation cohorts, No-Apnea
showed adequate performance in OSA screening, with
a discriminatory ability that was similar and indistinguishable
from the performance of either STOP-Bang or NoSAS.23
Although No-Apnea has been subsequently validated in
selected clinical populations,24–26 and displayed adequate pre-
dictive performance, some points deserve to be highlighted: i)
absence of subjective variables may result in more difficult
applicability, especially in regions with a lower prevalence of
OSA, such as in primary care; ii) presence of age ≥55 years,
already sufficient to classify individuals at high risk for the
diagnosis of OSA, possibly limits its use in older populations;
and iii) because it contains different scores for each parameter,
it may be difficult to adopt and implement, particularly in
general clinical practice settings.
Based on such concerns, we aimed to develop
a practical and concise questionnaire that would include
both objective and subjective variables, with yes-or-no
dichotomous answers. To this effect, we designed the
present study into two parts: i) derivation and validation
of a proposed tool for screening OSA in adults, and ii)
comparison with three other widely validated OSA screen-
ing instruments: No-Apnea score, STOP-Bang question-
naire, and NoSAS score.
Methods
Study Design and Patient Selection
This was a cross-sectional study, comprising the period from
January 2017 to June 2019, including adults which were con-
secutively referred for PSG evaluation due to suspected sleep
disordered breathing by their attending physicians. Then, all
subjects were grouped into two separate cohorts: derivation
(from January 2017 to February 2018) and validation (from
May 2018 to June 2019). Inclusion criteria consisted of indivi-
duals of both genders, aged ≥18 years and with suspected of
OSA,while exclusion criteriawere: previously diagnosedOSA,
use of home sleep study for diagnosis, incomplete clinical data
and technically inadequate PSG. In case the same individual
underwent more than one PSG, only the test with the longest
total sleep time was included. All sleep tests were conducted in
a Brazilian single-center located in the city of Rio de Janeiro:
SLEEP – Laboratório de Estudo dos Distúrbios do Sono.
On the evening of PSG, clinical, demographic and anthro-
pometric data were systematically obtained from all partici-
pants by trained sleep laboratory technicians: gender, age, body
mass index (BMI), NC, self-reported comorbidities (hyperten-
sion and diabetes mellitus), OSA-related symptoms (snoring,
observed apnea, gasping/choking, and tiredness), and Epworth
Sleepiness Scale (ESS).27 The ESS is an 8-item questionnaire
(each item is scored from0 to 3 points,with afinal score from0
to 24 points), which subjectively measures excessive daytime
sleepiness by a score ≥11 points.27 BMI was calculated divid-
ing the weight in kilograms by the square of the height in
meters (kg/m2), while NC (cm) was measured using a tape
measure, with its upper edge placed below the laryngeal pro-
minence and applied perpendicularly along the neck axis.
Ethical Considerations
The study protocol (No. 1.764.165) was approved by the
Research Ethics Committee of the Federal University of
Rio de Janeiro (UFRJ) and adhered to standard previously
set by the Declaration of Helsinki. All participants
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provided written informed consent, being that anonymity
of all recruited individuals was guaranteed throughout the
study process.
Screening Instruments
TheNo-Apnea (final score from0 to 9, high riskwith 3 ormore
points) contains two objective parameters: NC is scored in
three values: 1 (37.0–39.9 cm), 3 (40.0–42.9 cm), and 6 (-
≥43.0 cm), while age is scored as follows: 1 (35–44 years), 2
(45–54 years), and 3 (≥55 years).23 The STOP-Bang (final
score from 0 to 8, high risk with 3 or more points) consists of
8 yes-or-no questions (1 point for each affirmative answer):
loud snoring, tiredness, observed apnea, hypertension, BMI >
35 kg/m2, age >50 years, NC > 40 cm, and male gender.10 The
NoSAS allocates 4 points for having aNC>40 cm, 3 points for
having a BMI of 25–29 kg/m2 or 5 points for having a BMI ≥
30 kg/m2, 2 points for habitual snoring, 4 points for age >55
years, and 2 points for men; this instrument is considered
positive with a score ≥8 points (from 0 to 17 points).17
Sleep Studies
All subjects underwent an attended, in-lab PSG (EMBLA®
S7000, Embla Systems, Inc., Broomfield, Colorado, United
States) consisting of continuous monitoring of electroencepha-
logram, electrooculogram, electromyogram (chin and legs),
electrocardiogram, airflow, thoracic and abdominal impedance
belts, oxygen saturation, snoring microphone and sensors for
body position. Polysomnographic records were manually inter-
preted by two board-certified sleep physicians, according to
a guideline previously published in 2012 by the American
Academy of Sleep Medicine (AASM),28 which were blinded
to the values of all screening instruments collected prior to PSG.
Apneas were classified from a drop ≥90% of baseline airflow
lasting at least 10 s, while hypopneas were classified from
a ≥30% pre-event drop over ≥10 s associated with desaturation
of oxygen ≥3% or an arousal.28 The AHI was calculated as the
number of apnea plus hypopnea/total sleep time (in hours).
Polysomnographic diagnosis of OSA was based on apnea/
hypopnea index (AHI) ≥5.0/h and its severity was classified
as follows: ≥5.0/h as any OSA (OSA≥5), ≥15.0/h as moderate/
severe OSA (OSA≥15), and ≥30.0/h as severe OSA (OSA≥30).
Statistical Analysis
Data analysis was carried out using SPSS forWindows (version
21.0; SPSS; Chicago, IL, United States). Results are presented
as mean ± standard deviation for continuous variables and as
frequency (n) with percentage (%) for categorical variables.
The groups were compared using the chi-square test for
categorical variables, while Student’s t-test and univariate ana-
lysis of variance (ANOVA) were used for numerical variables.
Themodeling of the proposed instrument was initially based on
10 variables often associated with OSA diagnosis: male gender,
age ≥50 years, NC ≥40 cm, BMI ≥30 kg/m2, loud snoring,
observed apnea, hypertension, diabetes mellitus, tiredness, and
gasping/choking. The chosen cutoff points for age and BMI
were based on the highest odds ratio (OR) obtained for OSA≥15
diagnosis: age ≥50 years (OR: 1.911; 95% confidence interval
[CI]: 1.668–2.189) versus age ≥55 years (OR: 1.817; 95% CI:
1.566–2.108) and BMI ≥ 30 kg/m2 (OR: 2.563; 95% CI: 2.-
243–2.928) versus BMI ≥ 35 kg/m2 (OR: 2.088; 95% CI:
1.826–2.388). Similarly, we used loud snoring and not the
presence of snoring by obtaining a higher OR for OSA≥15
diagnosis: OR: 5.454 (95% CI: 3.972–7.490) versus 3.801
(95% CI: 3.300–4.377). The NC ≥ 40 cm has been chosen as
this is the threshold used in the STOP-Bang and NoSAS
instruments.10,17 Firstly, these 10 chosen variables were evalu-
ated by univariate analyses, where the outcome was an AHI ≥
15.0/h, a conventionally accepted cutoff point for classifying
clinically relevant OSA. Sequentially, clinically relevant vari-
ables (p < 0.10 in the univariate analysis) were included in
a multivariate logistic regression model with AHI ≥ 15.0/h
being the dependent variable. Performance of the newly devel-
oped instrument was calculated as follows: i) discrimination by
the Receiver Operating Characteristic (ROC) curves and area
under the curve (AUC); ii) calibration assessed by the Hosmer–
Lemeshow test (p < 0.05 was considered as poor calibration);
iii) 2x2 contingency tables (sensitivity, specificity, positive pre-
dictive value [PPV], and negative predictive value [NPV]); and
iv) correlation through the Spearman coefficient (rs). As
Hosmer–Lemeshow test is very sensitive to sample size, we
chose a smaller subset of randomly selected patients (n = 1000)
to evaluate calibration. An AUC > 0.7 was considered as
clinically significant, being that AUCs were compared using
a previously described algorithm.29 All predictive parameters
were calculated at three AHI thresholds (5.0/h, 15.0/h, and
30.0/h) and reported with their respective 95% CIs. A two-
tailed p-value <0.05 was considered as statistically significant.
Results
The flowchart of the study is showed in Figure 1, being that
7377 subjects were consecutively allocated into two indepen-
dent cohorts: one for derivation (n = 3771) and one for valida-
tion (n = 3606). According to Table 1, no clinical or
polysomnographic parameter showed a statistically significant
difference between derivation and validation cohorts, except for
total sleep time (p = 0.047) and arousal index (p = 0.031).
Dovepress Duarte et al
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Prevalence of OSA≥5, OSA≥15, and OSA≥30 showed no statis-
tically significant differences between derivation and validation
cohorts: 79.1% versus 78.8% (p = 0.753), 57.7% versus 57.0%
(p = 0.604), and 37.8% versus 35.7% (p = 0.070); respectively.
Modeling
Table 2 shows the seven independent predictive parameters for
screening for OSA≥15. Diabetes mellitus and gasping/choking,
although initially tested as possible OSA predictors, were
subsequently excluded because they are not independent vari-
ables for OSA≥15 diagnosis. As can be seen in Table 2, these
seven parameters were ranked according to adjusted OR: the
main parameter was male gender, followed by age ≥50 years,
loud snoring, BMI ≥ 30 kg/m2, NC ≥ 40 cm, observed apnea,
and hypertension.
From these data, several possible models were tested using
the main clinical parameters previously found. Figure 2 sum-
marizes the discrimination of possible models containing from
3 to 7 parameters, which exemplifies why a 4-item model was
ultimately chosen, since discriminatory power did not signifi-
cantly increase with the addition of a 5th (NC ≥ 40 cm), 6th
(observed apnea) or 7th variable (hypertension). This 4-item
instrument, because it contains only yes-or-no dichotomous
answers, reaches a final score of 0–4 points (Table 3), being
later named by the acronym GOAL (gender, obesity, age, and
loud snoring) questionnaire.
All individuals aged ≥ 18 years referred for 
sleep-lab from January 2017 to February 2018   
(n = 4,109)
338 patients were excluded:
Incomplete data and/or inadequate PSG (n = 235)
Diagnosis with an at-home sleep test (n = 47)
OSA previously diagnosed (n = 39)
Refuse to sign the consent form (n = 17)
Derivation cohort    
(n = 3,771)
All individuals aged ≥ 18 years referred for 
sleep-lab from May 2018 to June 2019   
(n = 3,948)
342 patients were excluded:
Incomplete data and/or inadequate PSG (n = 227)
Diagnosis with an at-home sleep test (n = 51)
OSA previously diagnosed (n = 48)
Refuse to sign the consent form (n = 16)
Validation cohort 
(n = 3,606)
Figure 1 The flowchart of the patients.
Abbreviations: OSA, obstructive sleep apnea; PSG, polysomnography.
Duarte et al Dovepress
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Predictive Parameters
Mean AHI values increased linearly in parallel with
increasing GOAL questionnaire scores (from 0 to 4
points): i) derivation cohort: from 3.6 ± 5.7/h to 53.3 ±
26.1/h (p-value for trend <0.001) and ii) validation
cohort: from 3.6 ± 5.8/h to 50.8 ± 27.1/h (p-value for
trend <0.001); Figure 3. In both datasets, GOAL was
positively correlated with AHI: rs = 0.559 with p < 0.001
(derivation cohort) and rs = 0.554 with p < 0.001 (vali-
dation cohort). In the derivation cohort, GOAL question-
naire showed adequate calibration for screening of
OSA≥5, OSA≥15, and OSA≥30 assessed by Hosmer–
Lemeshow test: 11.563 (p = 0.172), 5.135 (p = 0.743),
and 5.355 (p = 0.719); respectively. Similarly, in the
validation cohort, GOAL displayed adequate calibration
for screening of OSA≥5, OSA≥15, and OSA≥30 assessed
by Hosmer–Lemeshow test: 9.855 (p = 0.197), 3.921
(p = 0.864), and 5.799 (p = 0.670); respectively.
Predictive performance of the GOAL questionnaire is
shown in Table 4 (derivation cohort). We used a cutoff
point ≥2 to classify patients at high risk for OSA. This
strategy focused on privileging sensitivity over specificity,
aiming at reducing the false-negative rate. The frequency
of subjects classified as high risk for OSA through the four
screening instruments is shown in Figure 4.
Table 5 compares GOAL questionnaire with three other
previously validated tools: No-Apnea, STOP-Bang, and
NoSAS. In the derivation cohort, for screening of OSA≥5,
OSA≥15, and OSA≥30, GOAL questionnaire presented sensi-
tivities ranging from 83.3% to 94.0% and specificities ran-
ging from 62.4% to 38.5%. In the validation cohort, for
screening of OSA≥5, OSA≥15, and OSA≥30, GOAL question-
naire showed sensitivity values ranging from 83.7% to
94.2% and specificity values ranging from 63.4% to 37.7%.
In both cohorts, for diagnosis of OSA≥5, OSA≥15, and
OSA≥30, STOP-Bang always presented the highest sensitiv-
ity, while NoSAS always presented the highest specificity. In
both datasets and at all OSA severity levels, GOAL ques-
tionnaire showed high sensitivity. As expected, for all four
instruments, as AHI thresholds increased, a corresponding
increase in sensitivity and a reduction in specificity occurred.
Table 1 Patient Characteristics
Parameters Derivation
Cohort
(n = 3771)
Validation
Cohort
(n = 3606)
p
Clinical data
Male gender (%) 1983 (52.6) 1961 (54.4) 0.123
Age (years) 45.9 ± 14.6 45.7 ± 14.6 0.593
BMI (kg/m2) 33.1 ± 7.9 32.9 ± 7.7 0.437
NC (cm) 40.5 ± 5.0 40.5 ± 4.8 0.998
ESS (points) 9.8 ± 5.0 9.8 ± 5.1 0.766
Hypertension (%) 1531 (40.6) 1404 (38.9) 0.147
Diabetes mellitus (%) 470 (12.5) 436 (12.1) 0.645
Loud snoring (%) 2465 (65.4) 2291 (63.5) 0.103
Observed apnea (%) 1893 (50.2) 1847 (51.2) 0.389
Gasping/choking (%) 1503 (39.9) 1488 (41.3) 0.226
Tiredness (%) 2711 (71.9) 2607 (72.3) 0.716
Polysomnographic data
Total sleep time (min) 338.5 ± 71.7 342.1 ± 68.2 0.047
NREM sleep stage (%) 83.6 ± 7.8 83.4 ± 7.8 0.296
REM sleep stage (%) 15.9 ± 7.8 16.2 ± 7.9 0.179
Arousal index (n/h) 31.1 ± 26.0 29.8 ± 24.8 0.031
AHI (n/h) 28.9 ± 28.1 27.7 ± 26.9 0.058
Mean SpO2 (%) 93.5 ± 3.2 93.4 ± 3.5 0.528
Nadir SpO2 (%) 81.8 ± 9.3 81.9 ± 9.4 0.680
AHI (n/h)
≥5.0/h (%) 2984 (79.1) 2842 (78.8) 0.753
≥15.0/h (%) 2174 (57.7) 2057 (57.0) 0.604
≥30.0/h (%) 1424 (37.8) 1288 (35.7) 0.070
Note: Numeric and categorical variables were reported as mean ± SD and n (%),
respectively.
Abbreviations: BMI, body mass index; NC, neck circumference; ESS, Epworth
Sleepiness Scale; NREM, non-rapid eye movement; REM, rapid eye movement; AHI,
apnea/hypopnea index; SpO2, oxygen saturation.
Table 2 Univariate and Multivariate Analyses of Clinical Parameters
According to AHI ≥ 15.0/h (Derivation Cohort; n = 3771)
Parameters Univariate Analysis Multivariate Analysis
Unadjusted
OR (95% CI)
p Adjusted OR
(95% CI)
p
Male gender 3.394
(2.964–3.885)
< 0.001 2.831
(2.356–3.402)
< 0.001
Age ≥ 50 years 1.911
(1.668–2.189)
< 0.001 2.572
(2.159–3.064)
< 0.001
Loud snoring 5.454
(3.972–7.490)
< 0.001 2.402
(2.037–2.832)
< 0.001
BMI ≥ 30 kg/m2 2.563
(2.243–2.928)
< 0.001 2.315
(1.932–2.774)
< 0.001
NC ≥ 40 cm 4.323
(3.759–4.972)
< 0.001 1.937
(1.602–2.343)
< 0.001
Observed apnea 2.894
(2.531–3.309)
< 0.001 1.670
(1.412–1.975)
< 0.001
Hypertension 2.147
(1.874–2.459)
< 0.001 1.254
(1.060–1.484)
0.008
Diabetes mellitus 1.841
(1.494–2.269)
< 0.001 1.140
(0.892–1.457)
0.295
Gasping/choking 1.342
(1.175–1.533)
< 0.001 1.022
(0.867–1.204)
0.799
Tiredness 0.913
(0.790–1.054)
0.226 – –
Abbreviations: AHI, apnea/hypopnea index; BMI, body mass index; NC, neck
circumference; OR, odds ratio; CI, confidence interval.
Dovepress Duarte et al
Nature and Science of Sleep 2020:12 submit your manuscript | www.dovepress.com
DovePress
61
 
N
at
ur
e 
an
d 
Sc
ie
nc
e 
of
 S
le
ep
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
13
6.
11
5.
1 
on
 0
7-
Fe
b-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Comparing Discriminatory Ability
Figure 5 shows the discrimination obtained by the four
screening instruments: in both cohorts and at all OSA
severity levels, there were no statistically significant dif-
ferences in the discriminatory ability of the GOAL ques-
tionnaire when compared to No-Apnea, STOP-Bang or
NoSAS in screening of OSA≥5, OSA≥15, and OSA≥30.
Discussion
Current findings show that in a sleep-lab setting, a simple and
practical 4-item model, which we have denominated GOAL
questionnaire (male gender, obesity with BMI ≥30 kg/m2, age
≥50 years, and loud snoring), achieves adequate and reproduci-
ble predictive performance for OSA screening at all severity
levels. Furthermore, its discriminatory ability was similar from
that of three previously validated and widely used screening
instruments for OSA: No-Apnea score, STOP-Bang question-
naire, and NoSAS score. Moreover, obtaining score ≥2 versus
<2 points to rank, respectively, at high or low risk allowed an
increase in specificity values compared to No-Apnea, while
concurrently preserving a relatively high sensitivity, especially
at most severe levels.
Sensitivity and specificity of a screening model are
usually inversely related and high sensitivity often comes
3-item: 0.727 (0.710-0.743) 
4-item: 0.765 (0.750-0.780)
5-item: 0.779 (0.764-0.793)
6-item: 0.784 (0.770-0.800)
7-item: 0.783 (0.768-0.797)
Figure 2 Graphical representation of several models sequentially constructed with the main independent variables for screening of moderate/severe obstructive sleep apnea
(OSA≥15). 3-item model: male gender, age ≥50 years, and loud snoring; 4-item model: 3-item model plus body mass index ≥30 kg/m
2, 5-item model: 4-item model plus neck
circumference ≥40 cm, 6-item model: 5-item model plus observed apnea, and 7-item model: 6-item model plus hypertension. The 3-item model reported discrimination
statistically lower than that obtained by 4-item model (p < 0.001). The 4-item model had a similar discrimination when compared to the 5-item, 6-item or 7-item models
(p-values: 0.184, 0.070, and 0.086; respectively). Estimates reported as area under the curve (95% confidence interval).
Table 3 The GOAL Questionnaire
Parameters Points
G - Male gender No = 0 Yes = 1
O - Obesity: body mass index ≥ 30 kg/m2 No = 0 Yes = 1
A - Age ≥ 50 years No = 0 Yes = 1
L - Loud snoring No = 0 Yes = 1
Note: The points for each variable are added, totaling a final score of 0–4 points.
Duarte et al Dovepress
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at the expense of specificity.8,30 In the context of OSA,
which is a very prevalent disease and often associated with
significant morbidity, it may be more important that the
screening method has high sensitivity, with consequent
reduction in the false-negative rate.8,30 As expected, all
four screening instruments (GOAL, No-Apnea, STOP-
Bang, and NoSAS) showed increased sensitivity in parallel
with increasing AHI thresholds (from 5.0/h to 30.0/h). On
the other hand, specificity decreased in the most severe
forms of OSA, which can result in a considerable number
of false positives.
Although our newly developed questionnaire contains
twice as many parameters as No-Apnea, it may be easier to
respond, score and interpret, since its construct is predicated
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Figure 3 Mean apnea/hypopnea index (AHI) values obtained by polysomnography according to GOAL questionnaire scores (from 0 to 4 points).
Table 4 Predictive Parameters of the GOAL Questionnaire (Derivation Cohort; n = 3771)
GOAL Questionnaire Scores
≥ 1 versus < 1 ≥ 2 versus < 2 ≥ 3 versus < 3 4 versus < 4
AHI ≥ 5.0/h
Sensitivity 98.4 (98.0–98.8) 83.3 (82.6–84.1) 48.0 (47.4–48.5) 8.20 (8.00–8.30)
Specificity 20.5 (18.8–21.8) 62.4 (59.5–65.2) 88.9 (86.6–90.9) 99.5 (98.6–99.8)
PPV 82.4 (82.1–82.7) 89.4 (88.5–90.2) 94.3 (93.1–95.3) 98.4 (95.7–99.5)
NPV 77.4 (71.2–82.6) 49.7 (47.4–52.0) 31.1 (30.3–31.8) 22.2 (22.0–22.3)
AHI ≥ 15.0/h
Sensitivity 99.6 (99.2–99.8) 89.8 (88.7–90.8) 56.5 (55.3–57.7) 10.5 (10.0–10.8)
Specificity 12.5 (11.9–12.7) 48.0 (46.5–49.4) 81.8 (80.1–83.3) 98.6 (97.9–99.1)
PPV 60.8 (60.5–60.9) 70.1 (69.3–70.9) 80.9 (79.1–82.5) 91.2 (86.9–94.3)
NPV 95.7 (91.7–97.9) 77.5 (75.1–79.8) 58.0 (56.9–59.1) 44.7 (44.4–44.9)
AHI ≥ 30.0/h
Sensitivity 99.9 (99.4–100.0) 94.0 (92.8–95.1) 65.8 (63.9–67.7) 13.6 (12.6–14.5)
Specificity 8.80 (8.50–8.89) 38.5 (37.7–39.1) 75.2 (74.0–76.3) 97.6 (97.0–98.1)
PPV 39.9 (39.7–40.0) 48.1 (47.5–48.7) 61.6 (59.8–63.4) 77.6 (72.0–82.4)
NPV 99.0 (96.2–99.8) 91.4 (89.6–93.0) 78.4 (77.1–79.6) 65.1 (64.7–65.4)
Note: Data are presented as estimates (95% confidence intervals).
Abbreviations: AHI, apnea/hypopnea index; PPV, positive predictive value; NPV, negative predictive value.
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on yes-or-no answers leading to easy calculation of the cumu-
lative score and simple attribution of risk. In contrast, No-
Apnea contains several sub-items being scored from 0 to 9
points. Another noteworthy fact is that No-Apnea derivation
and validation study23 was designed with retrospectively
recruited subjects, while the present study was conducted
with two independent cohorts of prospectively enrolled sub-
jects. In addition, logistic regression employed for No-Apnea
model development23 was performed with binary outcome
(AHI ≥ 5.0/h), while in the development of the GOAL ques-
tionnaire we employed AHI ≥ 15.0/h, a threshold often impli-
cated as a clinically relevant demarcation for OSA. Our
recently proposed instrument contains only one subjective
variable (loud snoring), similar to NoSAS (presence of snor-
ing), but well below the STOP-Bangwhich has four subjective
variables (loud snoring, observed apnea, tiredness, and hyper-
tension). Using a limited number of subjective parameters
possibly could result in greater applicability of the instrument
and less possibility of bias.
Another feature of the current instrument is that by increas-
ing its scores (from 0 to 4 points) there was a linear increase in
AHI obtained by PSG. This property may further translate into
a valuable tool for health professionals in defining the level of
risk and relative certainty when attempting to identify those
patients with a higher or lower probability of having
a diagnosis of OSA. The risk escalation characteristic has also
been previously described with the STOP-Bang questionnaire,
whereby increasing values obtained from STOP-Bang (from 0
to 8 points) were associated with an increased likelihood of
having OSA.31
The four clinical parameters (gender, BMI, age, snoring)
employed for the elaboration of our screening instrument are
well-established predictive factors for OSA. Regarding clinical
symptomatology, men with OSA usually have typical symp-
toms such as snoring and observed apnea, while women with
OSAoften report symptoms that are considered atypical, such as
insomnia, morning headache, and fatigue.32,33 Based on poly-
somnographic findings, women have a lower prevalence of
OSA than men, but with a clear increase in frequency after
menopause.32,33 Unlike No-Apnea,23 the chosen measure of
obesity was BMI over NC: this finding may translate into
a better balance of its components between genders, since NC
is a variable that is arguably higher in men than in women.32–34
OSAprevalence increaseswith age,with some studies reporting
a high prevalence of OSA in the elderly.35 The only subjective
variable that was chosen in our model was loud snoring, since
snoring intensity increases as OSA becomes more severe.36 In
addition, this question from the STOP-Bang questionnaire “Do
you snore loudly?” has already undergone cross-cultural adapta-
tion to the Portuguese language spoken in Brazil.37
Limitations and Strengths
Our study has some limitations that should be highlighted: the
study population was based on sleep-lab referral patients
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Figure 4 Percentage of individuals assessed as high risk for diagnosis of obstructive sleep apnea by four screening instruments: GOAL questionnaire, No-Apnea score,
STOP-Bang questionnaire, and NoSAS score.
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(subjects with a high pretest probability), and therefore the
possibility of selection bias is plausible. As the predictive values
of a screening model are affected by disease prevalence,30,38
future studies should be conducted to assess the performance of
theGOALquestionnaire in other population groups. In addition,
itwas conducted in a single-center anddidnot preferably include
individuals belonging to populations with their own distinct
anthropometric characteristics (eg, Asian or African popula-
tions), thus requiring future additional external validation.
Conversely, we should also point out several features of the
present study that should strengthen the ability to implement the
proposed instrument: it was developed and validated from two
very large and representative cohorts, with prospectively
recruited participants undergoing the same diagnostic test for
OSA (overnight full PSG) and with the same diagnostic criteria
recommended by AASM.28
Conclusions
All instruments (GOAL questionnaire, No-Apnea score,
STOP-Bang questionnaire and NoSAS score) were found
to be adequate instruments for OSA screening at any
severity level. The use of these instruments can allow
Table 5 Predictive Parameters of the OSA Screening Models
Screening Instruments
GOAL No-Apnea STOP-Bang NoSAS
Derivation cohort
AHI ≥ 5.0/h
Sensitivity 83.3 (82.6–84.1) 84.3 (83.5–85.0) 87.2 (86.5–88.0) 71.5 (70.7–72.3)
Specificity 62.4 (59.5–65.2) 56.3 (53.4–59.2) 50.6 (47.7–53.4) 71.0 (68.1–73.8)
PPV 89.4 (88.5–90.2) 88.0 (87.2–88.8) 87.0 (86.2–87.7) 90.3 (89.4–91.3)
NPV 49.7 (47.4–52.0) 48.6 (46.0–51.0) 51.1 (48.2–53.9) 39.7 (38.0–41.2)
AHI ≥ 15.0/h
Sensitivity 89.8 (88.7–90.8) 89.8 (88.7–90.9) 91.7 (90.7–92.6) 79.0 (77.7–80.2)
Specificity 48.0 (46.5–49.4) 43.3 (41.8–44.7) 37.4 (36.1–38.7) 59.6 (57.9–61.3)
PPV 70.1 (69.3–70.9) 68.3 (67.5–69.1) 66.6 (65.9–67.3) 72.7 (71.5–73.8)
NPV 77.5 (75.1–79.8) 75.8 (73.2–78.2) 76.8 (73.9–79.4) 67.6 (65.6–69.5)
AHI ≥ 30.0/h
Sensitivity 94.0 (92.8–95.1) 93.2 (91.9–94.3) 95.6 (94.4–96.5) 85.3 (83.6–86.8)
Specificity 38.5 (37.7–39.1) 34.7 (33.9–35.4) 30.5 (29.8–31.1) 51.1 (50.1–52.1)
PPV 48.1 (47.5–48.7) 46.4 (45.8–47.0) 45.5 (44.9–45.9) 51.4 (50.4–52.4)
NPV 91.4 (89.6–93.0) 89.4 (87.3–91.2) 91.9 (89.8–93.6) 85.1 (83.4–86.7)
Validation cohort
AHI ≥ 5.0/h
Sensitivity 83.7 (82.9–84.4) 85.2 (84.4–86.0) 88.0 (87.2–88.8) 71.8 (71.0–72.6)
Specificity 63.4 (60.4–66.2) 56.8 (53.9–59.7) 52.1 (49.2–54.9) 70.2 (67.2–73.0)
PPV 89.5 (88.6–90.3) 88.0 (87.2–88.8) 87.2 (86.5–88.0) 89.9 (88.9–90.9)
NPV 51.1 (48.7–53.3) 50.8 (48.1–53.3) 53.9 (50.9–56.7) 40.1 (38.3–41.7)
AHI ≥ 15.0/h
Sensitivity 89.2 (88.0–90.2) 90.4 (89.3–91.5) 92.5 (91.5–93.5) 79.0 (77.7–80.3)
Specificity 46.8 (45.3–48.2) 42.5 (41.0–43.9) 37.8 (36.4–39.0) 58.5 (56.7–60.2)
PPV 69.0 (68.1–69.8) 67.6 (66.8–68.4) 66.4 (65.6–67.1) 71.6 (70.5–72.8)
NPV 76.5 (74.0–78.8) 77.0 (74.3–79.5) 79.2 (76.3–81.8) 67.7 (65.7–69.7)
AHI ≥ 30.0/h
Sensitivity 94.2 (92.8–95.3) 93.8 (92.4–95.0) 96.6 (95.5–97.5) 85.7 (83.9–87.4)
Specificity 37.7 (36.9–38.3) 33.4 (32.7–34.1) 30.0 (29.4–30.5) 49.8 (48.8–50.7)
PPV 45.6 (45.0–46.2) 43.9 (43.3–44.5) 43.4 (42.9–43.8) 48.7 (47.7–49.6)
NPV 92.1 (90.3–93.6) 90.6 (88.6–92.4) 94.0 (92.1–95.6) 86.2 (84.5–87.9)
Note: Data are presented as estimates (95% confidence intervals).
Abbreviations: AHI, apnea/hypopnea index; PPV, positive predictive value; NPV, negative predictive value.
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improved allocation of patients into corresponding priori-
ties, thus enabling better prioritization of financial
resources. In both cohorts, there was no superiority of
one given tool over the other, which shows a possible
great practical applicability of the GOAL questionnaire,
as it contains only four clinical parameters easily obtained
during any evaluation of a patient with suspected OSA. As
with any population study, future exploration for other
world regions and different clinical settings will be critical
for widespread implementation of such simple and concise
screening tool.
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